Utama › Kanser Hati (Karsinoma Hepatoselular) › Missouri › St. Louis
Kajian klinikal Kanser Hati (Karsinoma Hepatoselular) di St. Louis, MO
13 kajian untuk Kanser Hati (Karsinoma Hepatoselular) sedang mencari peserta di lokasi dalam dan sekitar St. Louis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Mengambil pesertaSukarelawan sihat dialu-alukan
- Washington University School of Medicine, St Louis
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Mengambil pesertaFasa 1/2
- Research Facility, St Louis
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Mengambil pesertaFasa 1/2
- Siteman Cancer Center, St Louis
- Barnes-Jewish Hospital, St Louis
- Washington University School of Medicine - Siteman Cancer Center, St Louis
- dan 5 lagi
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
Mengambil peserta
- Siteman Cancer Center Washington University, St Louis
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Mengambil pesertaFasa 3
- Research Site, St Louis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Mengambil pesertaFasa 1/2
- Washington University School of Medicine, St Louis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Washington University School of Medicine, St Louis
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Mengambil pesertaFasa 3
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- dan 2 lagi
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Mengambil pesertaFasa 1/2
- Research Site, St Louis
IDOV-Immune for Advanced Solid Tumors
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Mengambil peserta
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Mengambil pesertaFasa 1/2
- Washington University in St. Louis, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, St Louis
Kajian Kanser Hati (Karsinoma Hepatoselular) di bandar lain
- Houston, TX31 kajian
- New York City, NY24 kajian
- Dallas, TX19 kajian
- Los Angeles, CA19 kajian
- Boston, MA18 kajian
- Cleveland, OH18 kajian
- Chicago, IL16 kajian
- Philadelphia, PA16 kajian
- Pittsburgh, PA15 kajian
- San Francisco, CA14 kajian
- Orange, CA14 kajian
- Jacksonville, FL14 kajian
Kajian lain di St. Louis
- Kanser Paru-paru Bukan Sel Kecil73 kajian
- Kanser Payudara64 kajian
- Kanser Metastatik54 kajian
- Kanser Kolorektal50 kajian
- Kanser (semua jenis)46 kajian
- Kanser Prostat46 kajian
- Kanser Paru-paru39 kajian
- Kanser Ovari38 kajian
- Kanser Pankreas33 kajian
- Kanser Endometrium29 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher28 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.